# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- government rights

## BACKGROUND OF THE INVENTION

- introduce rheumatoid arthritis
- describe effects of RA
- discuss current treatments
- limitations of current treatments
- introduce mesenchymal stem cells
- describe MSC properties
- discuss MSC homing
- discuss MSC immunoregulation
- unmet medical needs

## BRIEF SUMMARY OF THE INVENTION

- introduce LLP2A peptidomimetic ligand
- describe conjugate with bisphosphonate drug
- method for reducing arthritis pain
- method for reducing cartilage and bone destruction
- method for treating primary inflammatory disease
- composition enhances MSC delivery
- administering LLP2A-Ale and MSCs
- administering sequentially or concurrently
- local or systemic administration
- injection or intravenous administration
- treating rheumatoid arthritis or synovitis
- co-administering LLP2A-Ale and MSCs
- subtherapeutic dose of MSCs
- series of doses separated by intervals
- treating inflammatory disease or disorder
- enhancing anti-inflammatory property of MSCs
- administering LLP2A-Ale and MSCs

## DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

- introduce peptidomimetic ligand-bisphosphonate conjugates
- describe immunomodulatory effects

### II. Definitions

- define abbreviations
- define "a" or "an"
- describe principles of chemical bonding
- define "Ale" or "Alen"
- define "peptide"
- define "amino acid"
- define "salt"
- describe pharmaceutically acceptable salts
- define "hydrate"
- define "pharmaceutically acceptable excipient"
- define "isomers"
- define "mesenchymal stem cell"
- define "immunomodulation"
- define "patient" and "subject"

### III. Compositions for Treating Inflammation and Inflammatory Diseases

- introduce LLP2A-bisphosphonate conjugates
- describe bisphosphonate drugs
- provide examples of bisphosphonate drugs
- describe LLP2A compounds conjugated to bisphosphonate drugs
- provide formula for LLP2A-Ale
- describe salts, hydrates, solvates, prodrug forms, isomers, and metabolites
- list examples of salts
- describe acid addition salts
- describe solvated forms
- describe crystalline or amorphous forms
- describe enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms
- describe prodrugs
- describe synthesis of compounds
- introduce mesenchymal stem cells
- describe co-administration of conjugate and mesenchymal stem cells
- describe recruitment of endogenous mesenchymal stem cells
- describe sources of mesenchymal stem cells
- describe purification of mesenchymal stem cells
- describe administration of mesenchymal stem cells
- describe amount of mesenchymal stem cells to be administered
- describe pharmaceutical carrier for mesenchymal stem cells
- describe pharmaceutically acceptable liquid medium

### IV. Formulation and Administration

- formulate compositions for various administration routes
- describe oral preparations
- list types of oral preparations
- describe pharmaceutical compositions for oral administration
- specify carriers for oral administration
- describe parenteral preparations
- list types of parenteral preparations
- describe pharmaceutical compositions for parenteral administration
- specify carriers for parenteral administration
- describe topical preparations
- list types of topical preparations
- describe pharmaceutical compositions for topical administration
- specify carriers for topical administration
- describe solid form preparations
- list types of solid form preparations
- describe pharmaceutical compositions for solid form preparations
- specify carriers for solid form preparations
- describe liquid form preparations
- list types of liquid form preparations
- describe pharmaceutical compositions for liquid form preparations
- specify carriers for liquid form preparations
- describe oil suspensions
- list types of oil suspensions
- describe pharmaceutical compositions for oil suspensions
- specify carriers for oil suspensions
- describe emulsions
- list types of emulsions
- describe pharmaceutical compositions for emulsions
- specify carriers for emulsions
- describe slow release formulations
- list types of slow release formulations
- describe pharmaceutical compositions for slow release formulations
- specify carriers for slow release formulations
- describe unit dosage forms
- list types of unit dosage forms
- describe pharmaceutical compositions for unit dosage forms
- specify carriers for unit dosage forms
- describe methods for preparing dosage forms
- describe pharmaceutically acceptable salts
- describe administered dosages
- describe factors affecting dosages
- describe subtherapeutic dosages
- describe co-administration of conjugates and mesenchymal stem cells
- describe enhanced therapeutic effects
- describe reduced administration frequency
- describe reduced administration amount
- describe combination protocols with other therapeutic agents
- describe administration routes and schedules

### V. Methods of Treating Inflammation

- describe conjugates for treating inflammation
- promote anti-inflammatory response
- promote immune response
- enhance anti-inflammatory property of mesenchymal stem cells
- reduce signs or symptoms of arthritis pain
- reduce structural deterioration in arthritis
- specify individuals to be treated
- define inflammatory conditions, diseases, and disorders
- specify primary inflammatory diseases or disorders
- specify localized inflammatory conditions
- provide examples of inflammatory conditions
- provide examples of joints affected

### VI. Examples

- introduce example of LLP2A-Ale
- describe animal model of rheumatoid arthritis
- analyze therapeutic effects of LLP2A-Ale
- assess bone volume in mice with RA
- analyze effect of LLP2A-Ale on cytokine production
- compare cytokine profiles of bone marrow cells
- conclude LLP2A-Ale maintains healthy bone homeostasis

